I hope potential partners put value on the things Ozgold talks about.
Part of the reason sales are low is that research needs to be published and presented from the centres that are doing it in order to influence those that aren't. And the approval needs to include folfirinox treatment. And that research is still ongoing and costs $. For example, Besselink will definitely publish and present his external placement of oncosil when it happens, and then others will want to try. But he has to be funded.
I personally would think that companies must hopefully see the value in the US despite the need for a pivotal FDA approved RCT. As a result of the cost of that study, I would give up US rights for an upfront and royalty and keep the ROW. An upfront for US would fund the company through until hopefully the German authorities approve their trial, which then provides further cashflow. It's not the best outcome, sure, but the necessary one I think.
The 10% placement and the R&D rebate aren't going to make a material difference except as a bridge to the German trial. But that too would have to be approved soon in order to have the funds to keep the company going until the cashflows from that trial.
OSL Price at posting:
0.9¢ Sentiment: Hold Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)